IMMUNITYBIO, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
IMMUNITYBIO, INC. (IBRX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $5.76 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-03-03
- IMMUNITYBIO, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $1.61M, a 21.79% increase year-over-year.
- IMMUNITYBIO, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $1.42M, a 8.89% decline year-over-year.
- IMMUNITYBIO, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $1.38M, a 15.65% decline year-over-year.
- IMMUNITYBIO, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $1.35M, a 15.72% decline year-over-year.
- IMMUNITYBIO, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $5.76M, a 5.82% decline from fiscal 2023.
- IMMUNITYBIO, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $6.11M, a 3.03% increase from fiscal 2022.
- IMMUNITYBIO, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $5.93M, a 21.46% increase from fiscal 2021.
- IMMUNITYBIO, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $4.88M, a 5.26% decline from fiscal 2020.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $3.03M derived: sum of 2 quarters · filed 2025-03-03 | $4.41M derived: sum of 3 quarters · filed 2025-03-03 | $5.76M 10-K · filed 2025-03-03 |
| 2024-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.79M derived: sum of 2 quarters · filed 2024-11-12 | $4.14M 10-Q · filed 2024-11-12 | $5.47M derived: sum of 4 quarters · filed 2025-03-03 |
| 2024-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.73M 10-Q · filed 2024-08-12 | $4.05M derived: sum of 3 quarters · filed 2025-03-03 | $5.61M derived: sum of 4 quarters · filed 2025-03-03 |
| 2024-03-31 | $1.35M 10-Q · filed 2024-05-09 | $2.67M derived: sum of 2 quarters · filed 2025-03-03 | $4.22M derived: sum of 3 quarters · filed 2025-03-03 | $5.86M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.88M derived: sum of 2 quarters · filed 2025-03-03 | $4.51M derived: sum of 3 quarters · filed 2025-03-03 | $6.11M 10-K · filed 2025-03-03 |
| 2023-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.19M derived: sum of 2 quarters · filed 2024-11-12 | $4.79M 10-Q · filed 2024-11-12 | $6.44M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $3.23M 10-Q · filed 2024-08-12 | $4.88M derived: sum of 3 quarters · filed 2025-03-03 | $6.36M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $1.60M 10-Q · filed 2024-05-09 | $3.25M derived: sum of 2 quarters · filed 2025-03-03 | $4.72M derived: sum of 3 quarters · filed 2025-03-03 | $6.21M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $3.13M derived: sum of 2 quarters · filed 2025-03-03 | $4.61M derived: sum of 3 quarters · filed 2025-03-03 | $5.93M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.96M derived: sum of 2 quarters · filed 2023-11-09 | $4.28M 10-Q · filed 2023-11-09 | $5.66M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.81M 10-Q · filed 2023-08-08 | $4.19M derived: sum of 3 quarters · filed 2024-03-19 | $5.42M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $1.32M 10-Q · filed 2023-05-11 | $2.70M derived: sum of 2 quarters · filed 2024-03-19 | $3.93M derived: sum of 3 quarters · filed 2024-03-19 | $4.65M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $2.62M derived: sum of 2 quarters · filed 2024-03-19 | $3.33M derived: sum of 3 quarters · filed 2024-03-19 | $4.88M 10-K · filed 2024-03-19 |
| 2021-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.95M derived: sum of 2 quarters · filed 2022-11-09 | $3.50M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $714.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.27M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $1.55M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $5.16M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |